Urogen Pharma Ltd at Goldman Sachs Healthcare Conference Transcript
Good morning, everyone. We'll continue with the next session. My name is Paul Choi, and I cover the small and I cover small and mid-cap biotechnology sector here at Goldman Sachs. It's my pleasure to welcome UroGen to the conference here. Joining us from management here on stage to my immediate left is Dr. Mark Schoenberg, CMO, and to my far left, Jeff Bova, Head of Commercial. Also in the audience here, we have Dong Kim, CFO.
What we'll do is continue with the usual format. Maybe I'll turn it over to Mark maybe to make some high-level comments on the company, and then we'll go into Q&A. If anyone in the audience has questions along the way, please feel free to raise your hand. Also, if you have -- for those who are listening on the webcast, feel free to e-mail us questions and I'll be happy to read them anonymously.
So either to Mark or Jeff, maybe if you want to maybe start with some high-level comments on what maybe the outlook is for this year, and then we'll get into Q&A.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
